ArticleBreast cancer research and treatment2020

A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer.

Norikazu Masuda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.